Extracted from this filing and checked against the source text.
Auditor Changes
SEC 8-K Item 4.01/4.02
confidence 0.9
ZEVRA THERAPEUTICS, INC. reported that prior financial statements should not be relied upon.
- Action
- non reliance
- Auditor
- Ernst & Young LLP
Exact text from the filing
and for the fiscal years ended December 31, 2022 and December 31, 2021, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, (collectively, the “Prior Financial Statements”) should no longer be relied upon. In connection with the preparation of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”), the Audit Committee concluded that, in prior years it had not appropriately accounted for certain common stock warrants as liabilities. These errors led to understatements of derivative and warrant liability and additional paid-in capital and fluctuations in fair value adjustment related to derivative and warrant liability during the impacted periods. We estimate that the impacts to the periods reported in the Prior Financial Statements will result in an increase to previously reported fair valu
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ZEVRA THERAPEUTICS, INC. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $13.2M.
- Period
- fourth quarter and fiscal year ended December 31, 2023
- Revenue
- $13.2M
- Result
- reported results
Exact text from the filing
Corporate Updates Launch of OLPRUVA ® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M Conference call scheduled for today, March 28, 2024, at 4:30 p.m. ET Celebration, FL – March 28, 2024 – Zevra Therapeutics, Inc. (NasdaqGS:
View on SEC.gov